Clonal Stem Cell Selection for Homogeneous Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating pluripotent stem cells into specific cell types, such as neural or cardiomyocytes, result in heterogeneous cell populations, which complicates therapeutic applications and increases the risk of adverse effects like teratoma or neuroepithelial tumors during transplantation.
Innovation Solution
The development of methods to produce clonal populations of pluripotent stem cells with specific differentiation potentials, allowing for the enrichment of homogeneous cell types like neural cells, hepatocytes, or cardiomyocytes, by expanding individual cells into clonal populations and selecting those that can differentiate at least 50% into desired cell types, thereby reducing heterogeneity and potential side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional differentiation methods are used to generate cell populations for therapy, then cell supply is abundant, but cell population heterogeneity increases leading to teratoma risk
Solution Approach 1:
The patent segments the cell population by isolating and expanding individual cells into separate clonal lines. Each clone is then characterized for its differentiation potential, allowing selection of clones that produce homogeneous differentiated cell populations while maintaining abundant cell supply through expansion of selected clones.
Solution Approach 2:
The patent changes the parameter of cell population homogeneity by selecting clones based on their differentiation efficiency (at least 50% homogeneous for specific cell types). This parameter change eliminates teratoma risk while preserving cell quantity through expansion of selected homogeneous clones.
2Adaptability or versatility
If heterogeneous cell populations are produced, then cell diversity is high, but therapeutic safety decreases due to adverse effects
Solution Approach 1:
By segmenting the heterogeneous population into individual clones and characterizing each clone's differentiation potential, the method identifies clones that reliably produce homogeneous differentiated cells. This maintains cell diversity through clone selection while ensuring therapeutic safety by eliminating clones with teratoma-forming potential.
Solution Approach 2:
The patent employs self-service through automated characterization of clone differentiation potential and selection of clones meeting the 50% homogeneity criterion. This systematic approach ensures therapeutic safety while preserving the ability to generate diverse cell types through selective clone expansion.
3Manufacturing precision
If clonal expansion is performed to achieve homogeneity, then cell population purity increases, but time and resource requirements increase
Solution Approach 1:
The patent applies preliminary action by characterizing the differentiation potential of each clonal line before large-scale expansion. Clones are pre-screened to ensure they will produce at least 50% homogeneous differentiated cells, preventing waste of time and resources on clones that would not meet purity requirements.
Solution Approach 2:
By changing the parameter of clone selection criteria (requiring at least 50% differentiation homogeneity), the method achieves high cell population purity through selection rather than extensive purification, reducing the time and resources needed compared to conventional differentiation approaches.
Data Source
AI summary
Disclosed are methods for producing a clonal population of cells involving: a) obtaining a population of pluripotent or multipotent cells that have been expanded in vitro and maintained in an undifferentiated or essentially undifferentiated state; b) expanding individualized cells of the population into clonal populations of cells; and c) selecting one or more clonal population of cells determined to have the ability to differentiate into a population that is at least about 50% homogeneous for either neural cell types, hepatocytes, or cardiomyocytes. Also disclosed are clonal populations of cells produced by the methods of the present invention, and methods of treating disease in subjects involving administration of clonal cells of the present invention to a subject. Methods of screening test compounds that involve contacting a test compound with a clonal population of cells produced by the methods of the present invention are also set forth.